JP6346944B2 - 組み合わせ薬物療法 - Google Patents

組み合わせ薬物療法 Download PDF

Info

Publication number
JP6346944B2
JP6346944B2 JP2016515414A JP2016515414A JP6346944B2 JP 6346944 B2 JP6346944 B2 JP 6346944B2 JP 2016515414 A JP2016515414 A JP 2016515414A JP 2016515414 A JP2016515414 A JP 2016515414A JP 6346944 B2 JP6346944 B2 JP 6346944B2
Authority
JP
Japan
Prior art keywords
cancer
compound
combination
methyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016515414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530208A5 (enExample
JP2016530208A (ja
Inventor
グレスホック，ジョエル
アール バックマン，カーティス
アール バックマン，カーティス
チャールズ ブラックマン，サミュエル
チャールズ ブラックマン，サミュエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of JP2016530208A publication Critical patent/JP2016530208A/ja
Publication of JP2016530208A5 publication Critical patent/JP2016530208A5/ja
Application granted granted Critical
Publication of JP6346944B2 publication Critical patent/JP6346944B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016515414A 2013-09-19 2014-09-16 組み合わせ薬物療法 Expired - Fee Related JP6346944B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361879895P 2013-09-19 2013-09-19
US61/879,895 2013-09-19
PCT/US2014/055816 WO2015042029A1 (en) 2013-09-19 2014-09-16 Combination drug therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018101120A Division JP6563558B2 (ja) 2013-09-19 2018-05-28 組み合わせ薬物療法

Publications (3)

Publication Number Publication Date
JP2016530208A JP2016530208A (ja) 2016-09-29
JP2016530208A5 JP2016530208A5 (enExample) 2017-08-24
JP6346944B2 true JP6346944B2 (ja) 2018-06-20

Family

ID=52689320

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016515414A Expired - Fee Related JP6346944B2 (ja) 2013-09-19 2014-09-16 組み合わせ薬物療法
JP2018101120A Expired - Fee Related JP6563558B2 (ja) 2013-09-19 2018-05-28 組み合わせ薬物療法
JP2019135772A Pending JP2019196391A (ja) 2013-09-19 2019-07-24 組み合わせ薬物療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018101120A Expired - Fee Related JP6563558B2 (ja) 2013-09-19 2018-05-28 組み合わせ薬物療法
JP2019135772A Pending JP2019196391A (ja) 2013-09-19 2019-07-24 組み合わせ薬物療法

Country Status (10)

Country Link
US (1) US20160228446A1 (enExample)
EP (1) EP3046556A4 (enExample)
JP (3) JP6346944B2 (enExample)
KR (1) KR20160055911A (enExample)
CN (1) CN105530934A (enExample)
AU (1) AU2014321456B2 (enExample)
BR (1) BR112016005000A8 (enExample)
CA (1) CA2921156A1 (enExample)
RU (1) RU2016110546A (enExample)
WO (1) WO2015042029A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018158930A (ja) * 2013-09-19 2018-10-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2020097318A1 (en) * 2018-11-09 2020-05-14 Dana-Farber Cancer Institute, Inc. Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53967B1 (sr) * 2005-05-13 2015-08-31 The Regents Of The University Of California Diaril hidantoin jedinjenja kao antagonisti receptora androgena za lečenje raka
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101484587B (zh) * 2006-02-03 2014-02-12 英克隆有限责任公司 Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
LT2656841T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
SI3329775T1 (sl) * 2010-02-24 2021-09-30 Medivation Prostate Therapeutics Llc Procesi za sintezo spojin diariltiohidantoina in diarilhidantoina
MA34591B1 (fr) * 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
BR112013023028B1 (pt) * 2011-03-10 2021-09-21 Suzhou Kintor Pharmaceuticals, Inc Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e formulação farmacêutica tópica
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
CA2897559A1 (en) * 2013-01-09 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Combination
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2015042029A1 (en) * 2013-09-19 2015-03-26 Glaxosmithkline Llc Combination drug therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018158930A (ja) * 2013-09-19 2018-10-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法
JP2019196391A (ja) * 2013-09-19 2019-11-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法

Also Published As

Publication number Publication date
AU2014321456B2 (en) 2018-05-24
RU2016110546A3 (enExample) 2018-03-20
CA2921156A1 (en) 2015-03-26
EP3046556A4 (en) 2017-04-26
RU2016110546A (ru) 2017-10-24
US20160228446A1 (en) 2016-08-11
AU2014321456A1 (en) 2016-03-10
EP3046556A1 (en) 2016-07-27
CN105530934A (zh) 2016-04-27
WO2015042029A1 (en) 2015-03-26
JP6563558B2 (ja) 2019-08-21
BR112016005000A8 (pt) 2018-01-23
JP2016530208A (ja) 2016-09-29
KR20160055911A (ko) 2016-05-18
JP2019196391A (ja) 2019-11-14
JP2018158930A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
JP5718929B2 (ja) 組合せ物
JP4458746B2 (ja) 癌の治療方法
JP6355724B2 (ja) がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
JP2017500307A (ja) がんの処置のためのトラメチニブ、パニツムマブおよびダブラフェニブの組合せ
US20150273057A1 (en) Combination
JP6563558B2 (ja) 組み合わせ薬物療法
JP7235807B2 (ja) 組合せ物
US20170348329A1 (en) Combination Drug Therapy
HK40106558A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
US20190151319A1 (en) Combination comprising a btk inhibitor and an akt inhibitor
US20150352121A1 (en) Combination
HK1181971B (en) Benzimidazole derivatives as pi3 kinase inhibitors
HK1181971A (en) Benzimidazole derivatives as pi3 kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180528

R150 Certificate of patent or registration of utility model

Ref document number: 6346944

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees